Clay Siegall is the chief executive officer and president of Seattle Genetics. He founded the firm in 1998. Siegall is a scientist by training. He is particularly interested in targeted cancer therapies. Clay established Seattle Genetics based on his strong passion for helping patients to access viable cancer therapies. He also zeroes in on rigorous research, drug development practices, and scientific innovation. Through his visionary leadership, he has been able to enhance the growth of the company. Today, the company maintains its leadership status of developing anti-body drug conjugates. In 2011, Clay played an integral role in facilitating the approval of its first ADC product, ADCETRIS, by the FDA. An agreement between Seattle genetics and Takeda Pharmaceutical Company enabled the product to be distributed in different parts of the globe, considering that it has been approved in over 65 countries.
Under Clay Siegall’s leadership, the firm has entered into numerous strategic licenses with different renowned corporations for its ADC technology. These companies are GlaxoSmithKline, Genetech, Pfizer, and AbbVie. The strategic licenses have managed to bring in over $350 million. More than 20 ADCs are applying Seattle Genetics’ technology. In addition, Siegall has been at the forefront of enhancing the company’s capital raising activities. Through his efforts, he has been able to raise over $1.2 billion though private and public financing. Some of the capital was raised when the company made its first public offering in 2001.
Siegall has gained immense knowledge and experience by working for multiple firms. From 1991 to 1997, Siegall worked for Bristol-Myers Squibb Pharmaceutical Research Institute. In addition, Clay rendered his services for the National Cancer Institute besides the National Institute of Health. Siegall is an active member of the boards of Washington Roundtable, Ultragenyx, and Alder BioPharmaceuticals. Siegall has been a recipient of multiple awards, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences. He holds 15 patents.
Dr. Clay Siegall holds a PhD in genetics from the esteemed George Washington University. Additionally, he has a B.S in zoology from the celebrated University of Maryland. He has vast experience in the pharmaceutical industry.
As part of the distinguished team of directors of Mina Therapeutics Inc, Siegall helped in the advancement of the firm’s microRNA-based therapeutics. To this end, he was able to enhance the development of cancer therapies.